Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

US regulators have once again declined to approve Hengrui Pharmaceuticals' (SHA: 600276) PD-1 inhibitor camrelizumab, further delaying the drug's entry into the American market.

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...

For the study, investigators pitted the HER2-targeted antibody-drug conjugate against Eli Lilly’s VEGFR inhibitor Cyramza ... the FDA approved Enhertu in stomach cancer following prior treatment ...

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and ...

EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation ...